Nektar preclinical data

In a mouse model of melanoma, IV NKTR-214 given once every 9 days reduced mortality by 84% and delayed tumor growth vs. twice-daily aldesleukin. NKTR-214 also led to an 8-fold increase in CD8+ effector memory T cells and a 6-fold decrease in CD4+ T cells in the tumor compared to aldesleukin. Data were presented at the American Association for Cancer Research meeting in Washington, D.C. Nektar plans to submit an IND for NKTR-214 by year end 2014, with clinical testing slated to begin in late 2014-early 2015. The product is an immunostimulatory cytokine engineered to selectively activate IL-2 receptors on cytotoxic T cells. ...